• End date
    Feb 17, 2024
  • participants needed
  • sponsor
    Centre Chirurgical Marie Lannelongue
Updated on 18 November 2021
lung cancer
lung carcinoma


Immunological toxicities associated with immune checkpoint inhibitor (ICI) monoclonal antibodies are unpredictable autoimmune and inflammatory pathologies that can affect all treated patients. Some of these events are severe and occur in 15-20% of patients treated with Programmed Death 1 (PD-1) antibodies.

The study of cellular immunological characteristics within tissues affected by toxicities and the interactions between the different actors of these toxicities aims at improving the knowledge concerning the mechanisms of these toxicities, but also at being able to specify the unexpected effects of ICIs on cells of the immune system, outside the tumor microenvironment.

Diffuse infiltrative lung disease is one of the most frequent and severe toxicities encountered in patients treated with anti PD-(L)1; either for bronchial cancer, melanoma or any other type of cancer. Patients developing this type of complication benefit from cytological, bacteriological, mycological and molecular analyses of intra-alveolar constituents obtained by bronchoalveolar lavage (BAL) performed during bronchial fibroscopy as part of their routine care. These analyses help to confirm the diagnosis of alveolitis, to specify the cellular characteristics of alveolar inflammation and to eliminate differential diagnoses of ICI toxicity.

Condition carcinoma lung, Pulmonary Disease, Lung Neoplasm, Lung Disease, lung carcinoma, Bronchial Neoplasm, Lung Cancer
Treatment treatment with immunotherapy and diffuse infiltrative lung disease, Patients requiring carcinologic lobectomy
Clinical Study IdentifierNCT05117372
SponsorCentre Chirurgical Marie Lannelongue
Last Modified on18 November 2021


Yes No Not Sure

Inclusion Criteria

Adult subject ( 18 years old)
Patient having consented to the research
Group 1
Patient with cancer who was treated with immunotherapy
Appearance of CT lung abnormalities during immunotherapy, not related to cancer
With high suspicion of infiltrative lung disease
Pneumopathy (CTCAE version 5 classification)
Patients requiring bronchial fibroscopy with BAL
Groups 2
Patient with lung cancer with peripheral tumor
Requires surgical pulmonary lobectomy in the operating room

Exclusion Criteria

Patient treated or having been treated in the last 2 months with corticosteroid therapy
Patient treated with immunosuppressant and/or cyclophosphamide, and/or Anti-TNF in the last 12 months
Absence of consent
Patient under curatorship, guardianship or safeguard of justice
Pregnant woman
Group 1
Patient with respiratory failure
Groups 2
Patient with lung cancer with proximal or endobronchial tumor
Patients requiring bilobectomy or pneumonectomy
Patient who has been treated with immunotherapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note